Immutep : World Immunotherapy Congress 2019 presentation of TACTI-mel melanoma trial data

• soluble LAG-3 protein (eftilagimod alpha) with an anti-PD-1
  antibody (pembrolizumab): a new combination in

immuno-oncology.

Frédéric Triebel MD, PhD

World Immunotherapy Congress

Basel, October 15, 2019

Notice: Forward Looking Statements

The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they

contain should be read in conjunction with past and future announcements made by Immutep and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Immutep's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Immutep's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. Additionally, the INSIGHT investigator sponsored clinical trial described in this presentation is controlled by the lead investigator and therefore Immutep has no control over this clinical trial. This presentation should not be relied on as a recommendation or forecast by Immutep. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

2

LAG-3 as a Therapeutic Target

LAG-3 is widely expressed on tumor infiltrating lymphocytes (TILs) and cytotoxic T cells  Prime target for an immune checkpoint blocker

LAG-3/ MHC Class II Interaction

LAG-3

MHCII

APC*

T Cell

Notes:

* APC: antigen presenting cell

• Positive regulation of antigen presenting cells (APC)  increase in antigen presentation to cytotoxic CD8+
  T cells
• Negative regulation of LAG- 3+ T Cells

3

Targeting LAG-3/MHC II May Lead to Multiple Therapeutics in Numerous Indications

IMMUNOSTIMULATION

Efti

IMMUNOSUPPRESSION

APC

APC

Activator

Agonistic

mAb

IMP761

	MHCII
	Partnered with
Antagonistic
mAb

LAG-3LAG525

T Cell

Immuno-oncology	Viral Infections
Combination Therapies

Depleting

mAb

Partnered

with

GSK'781

Rheumatoid

Arthritis

LAG-3

T Cell

IBD	Multiple Sclerosis

4

Lead Program

Eftilagimod Alpha (IMP321)